Sorrento subsidiary to develop ADC cancer therapies

By The Science Advisory Board staff writers

February 8, 2021 -- Sorrento Therapeutics has formed a subsidiary company called Adnab that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates (ADC), each called an Adnab.

An Adnab is an immune complex of nanoparticle albumin-bound drug products, such as nab-paclitaxel, that are noncovalently conjugated with tumor-targeting monoclonal antibodies (mAbs), the firm said. The products will use Sorrento's G-MAB library of fully humanized mAbs to generate a portfolio of product candidates to target liquid and solid tumors with the potential to treat autoimmune diseases as well.

Dr. Svetomir Markovic, PhD, at the Mayo Clinic spearheads the project, and to date has formed nine potential Adnab candidates, including two that will be investigated in a U.S. Food and Drug Administration (FDA) supervised, investigator-initiated human trial. The company plans to file multiple investigational new drug (IND) applications this year; it also plans to request breakthrough therapy designation from the FDA in both ovarian and endometrial cancers.

Henry Ji, PhD, is Adnab's chairman and CEO.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here